Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | MRGPRX4 | Q96LA9 | 14/20 | 0.77 |
| ▸ | TTR | P02766 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481017 | 0.87 | MRGPRX4 (1.00) | ADRB2MRGPRX4TTRNR4A2 | |
| SCHEMBL22480802 | 0.85 | MRGPRX4 (1.00) | ADRB2MRGPRX4TTRNR4A2 | |
| SCHEMBL22480880 | 0.79 | MRGPRX4 (1.00) | MRGPRX4NR4A2ALDH1A1 | |
| SCHEMBL13236281 | 0.78 | TTR (1.00) | ADRB2MRGPRX4TTRALDH1A1GAA | |
| SCHEMBL8890296 | 0.78 | ALDH1A1 (0.61) | MRGPRX4TTRALDH1A1GAAMAPT | |
| SCHEMBL4273360 | 0.77 | MRGPRX4 (0.70) | MRGPRX4TTRMAPT | |
| SCHEMBL25219969 | 0.77 | MEN1 (0.67) | ADRB2ALDH1A1MAPT | |
| SCHEMBL30383911 | 0.77 | MEN1 (0.67) | ADRB2ALDH1A1MAPT | |
| SCHEMBL22481074 | 0.77 | MRGPRX4 (0.69) | ADRB2MRGPRX4 | |
| SCHEMBL22480892 | 0.77 | MRGPRX4 (1.00) | MRGPRX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| EP-4008716-A1 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008717-A2 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| WO-2020198537-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | ADRB2 217/4885MRGPRX4 1/4885TTR 4151/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | ADRB2 217/4885MRGPRX4 1/4885TTR 4151/4885 |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | ADRB2 211/4885MRGPRX4 1/4885TTR 4115/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | ADRB2 217/4885MRGPRX4 1/4885TTR 4151/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | ADRB2 217/4885MRGPRX4 1/4885TTR 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.